NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-HD-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to support and facilitate the development of new and/or improved contraceptive products for men and women.
Funding Opportunity PAR-18-664 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of neurological disease for use in multi-site clinical trials and clinical practice.
Funding Opportunity RFA-DE-19-003 from the NIH Guide for Grants and Contracts. The NIDCR-funded FaceBase data repository and knowledgebase (www.facebase.org) was established to advance craniofacial research by creating comprehensive datasets on craniofacial development and dysmorphologies and disseminating them to the wider craniofacial research community. Since FaceBases inception, the data management and integration hub has been charged with the critical functions of collecting datasets and analytic tools developed by dataset-generating spoke projects, curating and integrating those resources, and disseminating them to the wider research community through the FaceBase website. This Request for Applications (RFA) solicits renewal applications for the role of the Data Management and Integration Hub. As in the past, the FaceBase 3 hub will continue to be responsible for integration and presentation of existing FaceBase datasets, development or adoption of new approaches for data search and visualization, and outreach to the wider craniofacial research community. In addition, the hub will assume an important new mission, that of working with investigators within the craniofacial research community to make their datasets compatible with FaceBases data models, curating and integrating these new datasets with those already held by FaceBase.
Notice NOT-DA-18-006 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-17-028 from the NIH Guide for Grants and Contracts. This FOA seeks applications for clinical trials testing interventions targeting diabetes distress in individuals with T1D and/or their caregivers, with the goal of understanding whether lowering diabetes distress will improve glycemic control and quality of life.
Funding Opportunity RFA-DK-17-027 from the NIH Guide for Grants and Contracts. This FOA will support research to test approaches in the healthcare setting to using Patient-Reported Outcomes (PROs) as tools to enhance patient-centered treatment and improve outcomes in individuals with type 1 diabetes.
Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-020 from the NIH Guide for Grants and Contracts. Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.
Funding Opportunity RFA-DK-17-032 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for studies of etiology and pathogenesis related to development of type 1 diabetes (T1D) and/or its complications. Studies must involve subjects enrolled and followed in clinical trials, long term follow-up, or observational studies. This opportunity is intended to fund collaborative projects that bring new expertise and innovative approaches to enhance the value of major ongoing clinical research projects.
Funding Opportunity RFA-DK-17-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement is intended to foster the development of a diverse and highly trained workforce of endocrinologists to assume leadership roles related to the Nations biomedical and behavioral research efforts in the area of type 1 diabetes (T1D). T1D is an autoimmune disease that occurs in both children and adults. Therefore, the NIDDK will award physician scientist career development program (K12) grants to eligible institutions to provide a program to prepare adult and/or pediatric endocrinologists, selected by the institution, for careers in basic or clinical research related to T1D. This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. Scholars may also propose fundamental research or human subjects research that is not a clinical trial.
Funding Opportunity RFA-DK-17-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community (e.g. glucagon, somatostatin, C-peptide, insulin). The proposed assays should be highly reproducible, easily transferable to other laboratories, easy to multiplex, and validated in human plasma or serum.
Notice NOT-MH-18-022 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-592 from the NIH Guide for Grants and Contracts
Notice NOT-DA-18-061 from the NIH Guide for Grants and Contracts
Notice NOT-GM-18-017 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-658 from the NIH Guide for Grants and Contracts. The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences in human health and illness, including basic, preclinical, clinical, translational, and behavioral studies. Of special interest are studies relevant to understanding the significance of biological sex on cells and tissue explants; comparative studies of male and female tissues, organ systems and physiological systems; sex-based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research.
Funding Opportunity PAR-18-657 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. The scope of the research includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy consistent with the product's intended use in humans. For applicants submitting U54 renewal applications, research under this FOA should culminate in an optimized lead compound ready for advanced development. The Centers will contain at least three research projects supported by an administrative core, up to three optional scientific cores, and a research education core. Each research project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.
Funding Opportunity PAR-18-656 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include traditional clinical trials meant to develop and test behavior change interventions meant to prevent or treat dental, oral, or craniofacial conditions, as well as interventions that are used as tools to understand mechanisms of behavior change. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UH3 phase of the award will support the conduct of investigator-initiated intervention research at all stages, from early mech
Funding Opportunity PAR-18-655 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
Funding Opportunity PAR-18-654 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
Notice NOT-HD-18-004 from the NIH Guide for Grants and Contracts